tirzepatide script is finally here – what's the big deal? – GP Voice Tirzepatide with NAD+ in script

Missing a dose or injecting more than a week apart can cause hunger to return suddenly, making it harder to stick to your meal plan and weight loss goals

Will payers treat obesity as a chronic disease that deserves long term coverage

Structure Therapeutics is developing a portfolio of oral obesity drugs, with its oral GLP-1 receptor agonist aleniglipron (GSBR-1290) leading the charge

According to John Jakicic, an exercise physiologist at the University of Kansas, research has shown that people with obesity have more low-quality fibers in their muscles

This forms L-Carnitine L-Tartrate through an acid-base reaction